Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone612-379-8854
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$714.01 million
Profitability
Miscellaneous
Employees2,250
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Tuesday, October 29th. Shareholders of record on Friday, November 8th will be given a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 annualized dividend and a yield of 0.61%. The ex-dividend date is Thursday, November 7th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) issued its quarterly earnings results on Tuesday, October, 29th. The biotechnology company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.14. The biotechnology company had revenue of $183.24 million for the quarter, compared to analysts' expectations of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.98 earnings per share. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
7 brokerages have issued twelve-month target prices for BIO-TECHNE's shares. Their forecasts range from $165.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $211.50 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Has BIO-TECHNE been receiving favorable news coverage?
Headlines about TECH stock have been trending extremely negative on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIO-TECHNE earned a news impact score of -4.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BIO-TECHNE.
Are investors shorting BIO-TECHNE?
BIO-TECHNE saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 464,100 shares, a decline of 21.7% from the September 30th total of 592,400 shares. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is currently 3.0 days. Currently, 1.2% of the company's shares are sold short. View BIO-TECHNE's Current Options Chain.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).
What other stocks do shareholders of BIO-TECHNE own?
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
- Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
- Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
- Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
- Mr. Gerry Andros, VP of Sales and Marketing
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by a number of of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (2.51%), First Trust Advisors LP (1.06%), Riverbridge Partners LLC (1.05%), Conestoga Capital Advisors LLC (0.86%), Kornitzer Capital Management Inc. KS (0.52%) and Candriam Luxembourg S.C.A. (0.34%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.
Which major investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State of Tennessee Treasury Department, Kornitzer Capital Management Inc. KS, Tygh Capital Management Inc., Stephens Investment Management Group LLC, SG Americas Securities LLC, Conestoga Capital Advisors LLC and Rhumbline Advisers. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.
Which major investors are buying BIO-TECHNE stock?
TECH stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Candriam Luxembourg S.C.A., Retirement Systems of Alabama, California Public Employees Retirement System, Ascension Asset Management LLC, Comerica Bank, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $211.42.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $8.06 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.
What is BIO-TECHNE's official website?
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
